ArticleFrontiers in immunology2018
Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Pre-transplant microRNA serum profiles and association with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches.Frontiers in immunology · 2026Review
- Prediction of transplant rejection using non-coding RNAs.Molecular biology reports · 2025Review
- Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Clinical Significance of microRNAs in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation.Cancers · 2023Review
- Bioinformatics-integrated screening of systemic sclerosis-specific expressed markers to identify therapeutic targets.Frontiers in immunology · 2023Article
- The impact of epigenetic modifications on allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2023Review
- MicroRNA serum profiles and chronic graft-versus-host disease.Blood advances · 2022Article
- Circulating miR-455-3p, miR-5787, and miR-548a-3p as potential noninvasive biomarkers in the diagnosis of acute graft-versus-host disease: a validation study.Annals of hematology · 2021Article
- Profiling Tissue and Biofluid miR-155-5p, miR-155Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation is a curative treatment for numerous hematological malignancies. However, acute graft-versus-host disease (aGvHD) is a major complication affecting 40-70% of all transplant patients, whereby the earliest and most frequent presentation is in the skin. MicroRNAs play a role in varied biological process and have been reported as potential biomarkers for aGvHD. More recently, microRNAs have received added attention as circulatory biomarkers that can be detected in biofluids. In this study, we performed global microRNA expression profiling using a discovery cohort of diagnostic cutaneous aGvHD biopsies (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.